ライフサイエンスコーパス: mouse model

1 cy of CXCR4 in an apolipoprotein E-deficient mouse model.

2 trol airway inflammation in a humanized ILC2 mouse model.

3 growth in the BRAF V600E/PTEN-null melanoma mouse model.

4 ver metastases in an experimental metastases mouse model.

5 mmunogenicity of the RABV was evaluated in a mouse model.

6 in vivo using an orthotopic xenograft breast mouse model.

7 ory damage in the spinal cord after TAR in a mouse model.

8 established disease in the L (V) panamensis mouse model.

9 inib led to tumor regression in an ABC-DLBCL mouse model.

10 ectopic transcription and anemia in the Nan mouse model.

11 vo significance was assessed via a xenograft mouse model.

12 or in development of this region in a mutant mouse model.

13 number in a streptozotocin-induced diabetic mouse model.

14 wth arrest, and prolonged survival in an AML mouse model.

15 lated PD-1/PD-L1 in a Tgfbr1/Pten 2cKO HNSCC mouse model.

16 highly pathogenic and causes lethality in a mouse model.

17 c nerve proceeds unhindered in the Ccr2(-/-) mouse model.

18 elinated axons in the db/db type II diabetes mouse model.

19 CW can detect pulmonary micrometastases in a mouse model.

20 pathologies do not persist in the acute MPTP mouse model.

21 was examined using the flank skin infection mouse model.

22 and Cyp c 1-induced allergic symptoms in the mouse model.

23 dysfunction in a Duchenne muscular dystrophy mouse model.

24 ive improvements in an AD APP/PS1 transgenic mouse model.

25 zing a photoreceptor-specific, PKM2 knockout mouse model.

26 hisms within human xenograft-derived CTCs in mouse models.

27 liposomes can reliably cure local cancer in mouse models.

28 ial necroptosis and remodeling using genetic mouse models.

29 e (A375Ppuro and PANC-1) subcutaneous tumour mouse models.

30 of SPOP mutation in human prostate cancer or mouse models.

31 luence the onset of the AD-like phenotype in mouse models.

32 and NA-induced respiratory tract toxicity in mouse models.

33 ients in ways that resemble some but not all mouse models.

34 by using PGRN and IL-10 genetically modified mouse models.

35 en explored using rat Abs in immunocompetent mouse models.

36 ical studies, typically using cell lines and mouse models.

37 (Cdc73(+/L)/PTH-Cre and Cdc73(L/L)/PTH-Cre) mouse models.

38 nditional knockout [cKO]) and naturally aged mouse models.

39 ens junctions, and confirm these findings in mouse models.

40 on, ameliorate skin fibrosis in experimental mouse models.

41 sfunction also contributes to the disease in mouse models.

42 protocol generically applicable to different mouse models.

43 We showed that in a transgenic mouse model, activation of the UPR in early differentiat

44 In a solid tumor mouse model allowing simultaneous monitoring of anti-tum

45 ry of the disease in the Emu-Tcl1 (Tcl1) CLL mouse model and 68 CLL patients.

46 on in a high-fat diet (HFD) induced diabetic mouse model and a genetically engineered T2DM rat model.

47 tablished in vivo mild chronic hypoxia (MCH) mouse model and a new severe acute hypoxia (SAH) mouse m

48 ies in this issue of the JCI use a humanized mouse model and demonstrate that type I interferon (IFN)

49 ction of FDXR, we generated a Fdxr-deficient mouse model and found that loss of Fdxr led to embryonic

50 We used a repetitive (r)TBI mouse model and harvested the injured brain extracts fro

51 By using integrative metabolomics in a mouse model and human biopsies of prostate cancer, we id

52 pidermis is a chemokine-high niche in both a mouse model and human vitiligo.

53 of (18)F-FETrp in patient-derived xenograft mouse models and compared them with (11)C-AMT uptake.

54 bits hPXR in human hepatocytes and humanized mouse models and enhances the chemosensitivity of cancer

55 Mouse models and genetic studies suggest the involvement

56 s been established in genetically engineered mouse models and human tumor cells.

57 Additional exploration of astrocytes in HD mouse models and humans is needed and may provide new th

58 T exon 1) underlies the disease pathology in mouse models and that the HTT exon 1 gene product can se

59 SO7 had a similar effect in the BAC-Q72 SCA2 mouse model, and in both mouse models it normalized prot

60 pontaneous choroidal neovascularization in a mouse model, and the combination of anti-TLR2 and antiva

61 in vivo; (c) labelling of tumour antigens in mouse models; and (d) use in affinity fluorescence and s

62 ral characterization of the Chrna7 deficient mouse model appeared prudent.

63 ption of anxiety-related behavior, alternate mouse models are required to effectively analyze cogniti

64 arch, Vivian and colleagues utilize a unique mouse model, called Mitochondrial Nuclear eXchange mice,

65 2040 metabolites in common, suggesting that mouse models can be used to interrogate human lung metab

66 response using bioengineered cell lines and mouse models containing either isoform of the gamma-subu

67 e model T126, was chosen to generate in vivo mouse models containing orthotopic breast tumors for in

68 All four PTHS mouse models demonstrated exaggerated hippocampal long-t

69 s will be of potential use for monitoring HD mouse model disease progression and evaluating preclinic

70 Here, we generated a novel mouse model (eAA) with the erythroid-specific ablation o

71 to a non-self-antigen, a TCRbeta transgenic mouse model (EF4.1) expressing a limited, yet polyclonal

72 evel or abnormal behavioral responses in ASD mouse models, especially during an early developmental t

73 ial entorhinal cortex (mEC) neurons from the mouse model exhibit proexcitatory alterations in Na chan

74 In both genetic mouse models, expression and phosphorylation of Sestrin2

75 grew larger, setting the stage to translate mouse model findings to precision medicine in the clinic

76 red to a C3H/C57bl6 background to generate a mouse model for Alagille syndrome (Jag1(Ndr/Ndr) mice).

77 In a well-characterized mouse model for DM1 (HSALR mice), activation of AMPK sig

78 es and limitations of the HLA-DR4 transgenic mouse model for evaluating human C. trachomatis vaccine

79 resembling exosomes from an H-RasV12 myr-Akt mouse model for GBM are enriched for intracellular signa

80 These results comprehensively describe a mouse model for investigating E faecalis wound infection

81 ssion in the prostate-specific Pten deletion mouse model for prostate cancer.

82 Here, we show that, in a mouse model for the polyglutamine disease dentatorubral-

83 icine and are frequently used in preclinical mouse models for both mechanistic studies and screening

84 r tumour types) is limited by the paucity of mouse models for live imaging of distal pre-metastatic n

85 Thus, our studies, which have established mouse models for parathyroid tumours and uterine neoplas

86 assays can be applied to any of the existing mouse models for retinal disorders and may be valuable f

87 on in the skin, we have generated transgenic mouse models for tamoxifen-inducible de novo expression

88 Using mutant mouse models for the most common form of congenital deaf

89 lling tumor rejection, we assessed different mouse models for Treg depletion.

90 rganoids derived from genetically engineered mouse models (GEMMs), wild-type organoids engineered ex

91 Overexpressing exogenous MBNL1 in the DM1 mouse model has been shown to rescue the splicing defect

92 Several mouse models have been generated to study OPMD; however,

93 tases Shp1 and Shp2, knockout and transgenic mouse models have revealed distinct phenotypes and nonre

94 An HD mouse model heterozygous for CK2alpha' shows increased H

95 To test this hypothesis, we created a mouse model in which a portion of the sciatic nerve from

96 Using a transgenic mouse model in which FlnA is selectively depleted in mye

97 Using a genetic mouse model in which the gene encoding the GR is selecti

98 kin carcinogenesis, we utilized a transgenic mouse model in which the keratin 14 promoter drives expr

99 on of Mig-6 in P4 resistance, we generated a mouse model in which we specifically ablated Mig-6 in ut

100 sed genetically engineered and GL261-induced mouse models in combination with CX3CR1(GFP/WT);CCR2(RFP

101 line xenograft and patient-derived xenograft mouse models in vivo.

102 Here we develop several mouse models in which hypothalamic stem/progenitor cells

103 The study of both cancer-bearing mouse models in wild types and their corresponding contr

104 symptoms of IBD in the TNBS-induced colitis mouse model, indicating the potential of FOLH1/GCPII inh

105 The inactivation of Crkl in the mouse model induced developmental defects similar to tho

106 l-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model is the most widely used animal model for Par

107 t RPE degeneration in human-cell-culture and mouse models is driven by a noncanonical-inflammasome pa

108 ies, and their importance in both humans and mouse models is still unclear.

109 in the BAC-Q72 SCA2 mouse model, and in both mouse models it normalized protein levels of several SCA

110 ocytes isolated from a liver-specific GSD Ia mouse model (L-G6pc(-/-) mice) and performed real-time a

111 immunogenicity of the H7 HA in the humanized mouse model, leading to a greater than 4-fold increase i

112 nd degeneration, we have used the Cln3 (-/-) mouse model of a juvenile form of NCL.

113 Alzheimer's-like phenotypes in a transgenic mouse model of Abeta deposition.

114 tinct cellular and molecular mechanisms in a mouse model of ACD.

115 This may constitute the basis for a new mouse model of ACPA-positive RA.

116 We have combined a mouse model of acute cholestatic liver injury, partial b

117 sumption of canola oil on the phenotype of a mouse model of AD that develops both plaques and tangles

118 arm of the contact system, is increased in a mouse model of AD, and this cleavage is temporally corre

119 gy arising from JIP3 haploinsufficiency in a mouse model of AD.

120 miR-29a significantly improved survival in a mouse model of aGVHD while retaining graft-versus-leukem

121 Using a mouse model of allergic airway inflammation, we found th

122 tions was low, microglial proliferation in a mouse model of Alzheimer's beta-amyloidosis was increase

123 nucleotide (FAD) in fresh brain samples of a mouse model of Alzheimer's disease (AD).

124 Further, in a mouse model of AMR, in which C57BL/6.

125 promote sensitization to Pru p 3 in vivo, a mouse model of anaphylaxis to peach has been produced an

126 rain structure in a maternal Ube3a knock-out mouse model of AS.

127 ed PCSK9 hypomethylation and a translational mouse model of AUD showed that alcohol exposure leads to

128 Here, we utilized the Shank3B mutant mouse model of autism to investigate how Shank3 mutation

129 e impact of granzyme A deficiency in the NOD mouse model of autoimmune diabetes.

130 t to directly investigate GFAP turnover in a mouse model of AxD that is heterozygous for a disease-ca

131 Using a mouse model of bacterial sepsis, we found that the numbe

132 In a mouse model of basal ErbB2 receptor tyrosine kinase 2 (E

133 Administration of trehalose to a mouse model of Batten disease, a prototypical neurodegen

134 To test this hypothesis, we exploited a mouse model of beta-thalassemia intermedia, Th3/(+) We o

135 of cellular intoxication and pathology in a mouse model of botulism.

136 In a preclinical mouse model of breast cancer, CCL21-mediated recruitment

137 suppression of tumour growth in a transgenic mouse model of breast cancer.

138 We adapted a mouse model of CAUTI to investigate how catheterization

139 We used a transgenic mouse model of chronic lung disease induced by the overe

140 h in a BCR-ABL fusion protein kinase-induced mouse model of chronic myeloid leukemia (CML).

141 -17 induces spontaneous immunopathology in a mouse model of CNS inflammation.

142 In this study, a neonatal mouse model of critical pertussis is characterized, and

143 ance of this pathway in our IL-15 transgenic mouse model of CTCL by showing that interference with BR

144 ation and protein quality control, we used a mouse model of dilated cardiomyopathy driven by cardiac

145 The trisomic Ts65Dn mouse model of DS shows synaptic deficits and reproduces

146 e model and a new severe acute hypoxia (SAH) mouse model of DWMI activates the initial step of the IS

147 ng.SIGNIFICANCE STATEMENT In DYT1 transgenic mouse model of dystonia, PDE10A, a key enzyme in cAMP an

148 ity to reduce the severity of paralysis in a mouse model of EV-D68 infection: (1) human intravenous i

149 investigated the IMS-UPRmt in the G93A-SOD1 mouse model of familial ALS, since mutant SOD1 is known

150 Using a mouse model of foodborne L. monocytogenes infection, a r

151 in young and adult Fmr1 knock-out mice, the mouse model of fragile X syndrome (FXS).

152 1-expressing p53 null mice represent a novel mouse model of fusion-negative RMS.

153 developed a novel, simple, and reproducible mouse model of GC-induced OHT.

154 ation and rescued phenotypes in a transgenic mouse model of hereditary primary open-angle glaucoma.

155 onism is conclusively demonstrated using the mouse model of imiquimod-induced psoriasiform skin lesio

156 icant decrease in GAS fitness in a humanized mouse model of impetigo; the DeltafbaA mutant also exhib

157 Using a mouse model of inducible SOX2, which is broadly expresse

158 mbined with next-generation sequencing and a mouse model of infection, we have carried out a comprehe

159 e putative prohemorrhagic effect of NAC in a mouse model of intracranial hemorrhage induced by in sit

160 aternal, dendrimer nanoparticle (DNAC), in a mouse model of intrauterine inflammation.

161 sed cone density by 30-40% in the Rpe65(-/-) mouse model of Leber congenital amaurosis and reduced th

162 MP-monoclonal antibody (mAb) was tested in a mouse model of ligature-induced periodontitis ( n = 6-7/

163 We used a mouse model of maternal-diet induced obesity to define p

164 ormalized muscle structure and strength in a mouse model of MDC1A.

165 ded lethal myeloid disease in a NUP98-HOXD13 mouse model of MDS, confirming its role in disease progr

166 ated tumor progression in a BRAFV600E-driven mouse model of melanoma.

167 le of oncogenic KRAS in CRC, we engineered a mouse model of metastatic CRC that harbors an inducible

168 Conditional deletion of Mof in a mouse model of MLL-AF9-driven leukemogenesis reduced tum

169 onuclei arising from genome instability in a mouse model of monogenic autoinflammation, after exogeno

170 CD20, for its ability to image B cells in a mouse model of MS using PET.

171 This THPI was effective in vivo in a mouse model of multiple sclerosis, reducing clinical sev

172 An EL4 mouse model of non-Hodgkin lymphoma and a B16 mouse mode

173 Here we show that the treatment of a mouse model of OPMD with an adeno-associated virus-based

174 aling and cell death in RGCs, including in a mouse model of optic nerve injury, and show that the sam

175 In vivo, in a mouse model of P. gingivalis-induced calvarial bone reso

176 dorsal root ganglia, spinal slices, and in a mouse model of pain induced by NaV1.7 activation, Pn3a a

177 eport that tumor-associated macrophages in a mouse model of pancreatic ductal adenocarcinoma (PDAC) o

178 es degeneration of dopaminergic neurons in a mouse model of Parkinson's disease using 1-methyl-4-phen

179 Using a mouse model of peritonitis, we demonstrate that neutroph

180 f senescence in vitro Here we show that in a mouse model of prostate cancer, SIN3B provides a barrier

181 rcinoma of mouse prostate (TRAMP) transgenic mouse model of prostate cancer.

182 antibody had antitumor activity in the RENCA mouse model of RCC.

183 We show that, in a mouse model of replicative senescence, decline in muscle

184 In a transgenic mouse model of resectable PDAC, we investigated the coor

185 , mechanistic experiments were designed in a mouse model of resuscitated hemorrhagic shock and tissue

186 ation to cue-reinstated cocaine seeking in a mouse model of self-administration and relapse, and foun

187 rized a robust, consistent, and reproducible mouse model of severe exacerbation of chronic allergic a

188 ouse model of non-Hodgkin lymphoma and a B16 mouse model of subcutaneous melanoma are used to extract

189 ne levels and protection from mortality in a mouse model of systemic inflammatory response syndrome.

190 ver-positive and oligomeric tau species in a mouse model of tau accumulation, preserving neuronal hea

191 GM2 in the brain tissues of an asymptomatic mouse model of Tay-Sachs disease, a severe human ganglio

192 worsening of the AD phenotype in a relevant mouse model of the disease.

193 In a mouse model of TON, real-time noninvasive imaging reveal

194 In a mouse model of toxoplasmosis, pyrazolopyrimidine inhibit

195 itis, as well as maintain normoglycemia in a mouse model of type 1 diabetes.

196 a in the renal tubular epithelial cells of a mouse model of unilateral ureteral obstruction (UUO) and

197 tment of peripheral vestibular function in a mouse model of USH1C and reveal the potential for using

198 efore, the aim of this study was to set up a mouse model of vascular graft infections that closely mi

199 In our studies of mouse models of acute leukemia, we used high-resolution

200 red weekly versus daily steroid treatment in mouse models of acute muscle injury and in muscular dyst

201 in the absence of BACE1 S-palmitoylation in mouse models of AD amyloidosis.

202 ted in human stem cell derived astrocyte and mouse models of amyotrophic lateral sclerosis (ALS).

203 In mouse models of ASDs, there is mounting evidence of neur

204 genetically prone and experimentally induced mouse models of autoimmunity, increased serum levels of

205 e found that NET components were released in mouse models of both lipopolysaccharide(LPS)-induced sho

206 more, neonatal and interferon gamma knockout mouse models of C. parvum infection identified BKIs with

207 (18)F-FLT) uptake and tissue distribution in mouse models of cancer.

208 l and vascular deficits in chronic and acute mouse models of CCM3 loss in vivo, significantly reducin

209 Novel mouse models of Chlamydia, Haemophilus influenzae, influ

210 of prostate 4 (STEAP4) was highly induced in mouse models of colitis and in IBD patients.

211 Here, using a longitudinal study of various mouse models of colitis, we identified a serum miRNA sig

212 effects of SPDEF on beta-catenin activity in mouse models of colorectal cancer (CRC), CRC cell lines,

213 tion studies using DBA2/J and Nos3 (eNos) KO mouse models of diabetes, TEPP-46 treatment reversed met

214 Mouse models of folate-responsive neural tube defects (N

215 rvival in two patient-derived BTIC xenograft mouse models of GBM.

216 We used genetically engineered mouse models of glioma and quantitative metabolomics to

217 Finally, in mouse models of ICH, spleen shrinkage could be related t

218 Data mining of RNA-Seq experiments with mouse models of intestinal HIF-2alpha or Yes-associated

219 Various mouse models of liver regeneration after extended partia

220 diets (KDs) have shown beneficial effects in mouse models of mitochondrial myopathies, with induction

221 n of the TGFbeta pathway, we first generated mouse models of neoplastic disease with TGFbeta receptor

222 endothelium and abrogate angiogenesis in the mouse models of oxygen-induced retinopathy and laser-ind

223 s evaluating sleep and breathing patterns on mouse models of pathophysiology.

224 ne-1-phosphate receptor (S1PR) agonist, on 2 mouse models of PD.

225 In serum from human PDAC patients and mouse models of PDAC, we found that LIF titers positivel

226 cer metastasis in two conditional transgenic mouse models of PyMT-induced breast cancer.

227 In mouse models of retroviral AML transplantation, as well

228 Using mouse models of SARS-CoV pathogenesis, we have identifie

229 Here we test RNA-targeted therapies in two mouse models of spinocerebellar ataxia type 2 (SCA2), an

230 Moreover, in mouse models of spontaneous and induced AD-like lesions,

231 Mouse models of T. cruzi infection have been used to stu

232 y), but not acute myeloid leukemia (AML), in mouse models of these tumors.

233 The ability to easily label pericytes in any mouse model opens the possibility of a broad range of in

234 tical cultures of either from E18 transgenic mouse model or from rat E18 embryos that were transientl

235 We show here that in mouse models PFC dysfunction in Fragile X Syndrome (FX)

236 LPS-induced endotoxemia, we developed a new mouse model, PMN(DTR) mice, in which injection of diphth

237 n an oncogenic mutant Smo (SmoM2)-driven BCC mouse model prevented the formation of BCC through suppr

238 vents leading to the development of the ZIKV mouse model reported in Cell Host & Microbe.

239 periments using the non-obese diabetic (NOD) mouse model reported mucosal administration of T1D-relat

240 cancer invasion in xenograft and orthotopic mouse models, respectively.

241 wn of LAMB1 or K19 in subcutaneous xenograft mouse models resulted in significant loss of cells invad

242 ph node dissection, both clinically and in a mouse model, results in a marked increase in the number

243 engineered periosteum in a femoral allograft mouse model similar to fresh passaged (P3) young MSCs.

244 tor for osteoarthritis (OA), yet surgical OA mouse models such as destabilization of the medial menis

245 al anomalies in a heterozygous Bmp2-knockout mouse model, suggesting that haploinsufficiency of BMP2

246 Here, we describe a new mouse model suitable for such risk assessment, based on

247 auditory function after noise exposure in a mouse model system, measured by ABR.

248 iew provides an overview of different MLL-FP mouse model systems and discusses how well they have rec

249 x vivo (human liver microsomes) and in vivo (mouse) model systems.

250 ith an emphasis on exploitation of a "dirty" mouse model that better mimics the diverse infectious hi

251 firmed using a human-derived tumor xenograft mouse model that bicalutamide pre-treatment is associate

252 We describe an mTOR-driven mouse model that displays hepatosteatosis progressing to

253 A mouse model that recapitulates key histopathological fea

254 16 on epilepsy phenotypes in the Scn1a (+/-) mouse model that recapitulates many features of Dravet s

255 role of TTC19, by investigating a Ttc19(?/?) mouse model that shows progressive neurological and meta

256 Here we show, using Cu-deficient mouse models, that steady-state levels of ATP7A are lowe

257 r severe OXPHOS deficiency comparing several mouse models, that will deepen our understanding, open a

258 Unlike in mouse models, the mechanisms underlying SAg-associated i

259 In xenograft and genetically engineered mouse models, the WDR4/PML axis elevates intratumoral Tr

260 We utilized the apoE(-/-) mouse model to compare atherosclerotic plaque size and c

261 We used an HDM-driven asthma mouse model to compare the capacity of Jagged 1 and Jagg

262 Here, we utilized a humanized mouse model to recapitulate the low immunogenicity of H7

263 Here, we developed a mouse model to study forelimb adaptation to force field

264 unstable in humans, and we present a unique mouse model to study human circadian disorders with unst

265 ells (DCs) for their activation, we used the mouse model to test the hypothesis that, after lymphoid

266 herapy and provide a translational humanized mouse model to test the lifespan, safety, and functional

267 Here, we develop a new mouse model to transfer genes specifically into the prim

268 Here we used mouse models to examine host determinants that affect H.

269 pathogenic factor in CDM and provides novel mouse models to further examine roles for cotranscriptio

270 In this study, we created two RP mouse models to test whether dying, untreated rods negat

271 In mouse models, TRX80 was associated with a proinflammator

272 The majority of mouse models used in research involve knock-in (reporter

273 ry to treat gastric bacterial infection in a mouse model using clarithromycin as a model antibiotic a

274 ing neuroblastoma metastasis, we developed a mouse model using intracardiac injection and in vivo sel

275 m healthy liver in an experimentally arrived mouse model using noninvasive technique.

276 A conditional betaENaC MG knockout (KO) mouse model was generated to elucidate the pathogenesis

277 RPV1-lineage axons, a genetically engineered mouse model was used in which a fluorophore is expressed

278 Using an in vivo mouse model we demonstrate abnormal development of dendr

279 Using a PDGF-B-driven proneural glioma mouse model, we assessed a panel of tyrosine kinase inhi

280 Using a glioma mouse model, we demonstrate that doxorubicin-loaded (D)C

281 With a mouse model, we examined the effect of neonatal exposure

282 th purified VacA proteins and infection of a mouse model, we show that H. pylori deregulates mitochon

283 Using mouse models, we demonstrate that melanoma growth is dra

284 Using in vitro cell culture and in vivo mouse models, we showed that COUP-TFII hinders myogenic

285 DS AND To address the question, 2 transgenic mouse models were generated: a phospho-mimetic cTnIS200D

286 histocompatibility complex fully mismatched mouse models were used to evaluate the alloimmune respon

287 arboring wild-type alleles of GBA, A53T-SNCA mouse model) were exposed to a brain-penetrant GCS inhib

288 Purpose To assess in a mouse model whether early or late components of glucose

289 We have developed a double knockout mouse model, which also shows reduced muscle strength, b

290 es utilized the well-characterized Pax9(-/-) mouse model with a consistent cleft palate phenotype to

291 Using a mouse model with a naturally occurring WS-linked gain-of

292 ombining QTL mapping and RNA-Seq data from a mouse model with association studies in human case-contr

293 isease pathogenesis, we generated a knock-in mouse model with NB disruption mediated by 2 point mutat

294 used whole-genome bisulfite sequencing in a mouse model with nonrandom XCI to examine allele-specifi

295 Here, the authors generate a novel mouse model with titratable expression of DUX4, and show

296 karyocytes (MKs) and platelets, we created a mouse model with Vps34 deletion in the MK/platelet linea

297 choroidal neovascularization, and transgenic mouse models with deficient or spontaneous retinal/choro

298 V formation by generating a series of mutant mouse models with induced conditional deletion of TGF-be

299 e (WT) mice were crossed to produce pregnant mouse models with or without adiponectin deficiency.

300 rowth of MGC803 cells in vivo in a xenograft mouse model without observed toxicity.